Physician profile
Sandhya Bejjanki
NPI 1205037488
$2,741.69
in general payments reported to CMS, 2019-2025
41 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.59 · 2020: $15.27 · 2021: $23.94 · 2022: $247 · 2023: $487 · 2024: $804 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,416 · Education: $25.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.37 |
| Education | $25.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $245.49 | 2022-2025 | Lynparza, Enhertu, Calquence |
| Celgene Corporation | $227.42 | 2022-2025 | Reblozyl |
| Novartis Pharmaceuticals Corporation | $219.83 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $200.50 | 2022-2025 | Opdivo, Krazati, Eliquis |
| Merck Sharp & Dohme LLC | $134.94 | 2024-2025 | Lynparza, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $113.14 | 2022-2025 | |
| Gilead Sciences, INC. | $99.20 | 2023-2025 | Trodelvy |
| Daiichi Sankyo INC. | $88.39 | 2023-2025 | Enhertu, Datroway |
| Pfizer INC. | $88.03 | 2024-2025 | |
| Lilly USA, LLC | $87.90 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacosmos Therapeutics INC. | $87.65 | 2023-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $75.29 | 2023-2025 | Xpovio |
| Genentech USA, INC. | $71.60 | 2023-2025 | Venclexta, Tecentriq |
| Eisai INC. | $71.17 | 2022-2025 | |
| Pharmaessentia USA Corporation | $68.07 | 2024-2025 | Besremi |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.61 | 2024-2025 | Ojjaara, Jemperli |
| Array Biopharma INC | $65.69 | 2025 | Braftovi, Mektovi, Tukysa |
| Foundation Medicine, INC. | $58.70 | 2023 | |
| Incyte Corporation | $57.85 | 2022-2025 | Monjuvi |
| Regeneron Healthcare Solutions, INC. | $54.55 | 2023-2025 | Libtayo |
| Seagen INC. | $54.19 | 2023 | Adcetris, Padcev |
| Sobi, INC | $47.84 | 2024-2025 | |
| Stemline Therapeutics INC. | $39.96 | 2024 | Orserdu |
| Alexion Pharmaceuticals, INC. | $38.00 | 2024 | Ultomiris |
| Astellas Pharma US INC | $37.63 | 2023-2025 | Vyloy, Xtandi |
| Acrotech Biopharma INC. | $35.91 | 2021-2022 | |
| Beone Medicines USA, INC. | $31.49 | 2025 | Brukinsa |
| Recordati_rare_diseases_inc. | $30.93 | 2025 | Enjaymo |
| Caris Mpi, INC. | $27.19 | 2025 | Mi Cancer Seek |
| Geron Corporation | $25.38 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $25.28 | 2025 | |
| Tempus Ai, INC | $23.93 | 2024 | |
| Servier Pharmaceuticals LLC | $21.21 | 2024 | |
| Abbvie INC. | $19.72 | 2024 | |
| Amgen INC. | $17.86 | 2022 | |
| Springworks Therapeutics, INC. | $17.45 | 2025 | Gomekli |
| Shield Therapeutics INC | $15.99 | 2024 | |
| Boston Scientific Corporation | $15.27 | 2020 | |
| Janssen Biotech, INC. | $13.66 | 2025 | Talvey |
| Genzyme Corporation | $13.59 | 2019 | |
| Sirtex Medical INC | $6.19 | 2024 | Sir-Spheres Microspheres |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Bejjanki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.